Imlunestrant
Overview of the drug Imlunestrant
| Imlunestrant | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Imlunestrant is a novel selective estrogen receptor degrader (SERD) under investigation for the treatment of hormone receptor-positive breast cancer. It is designed to target and degrade the estrogen receptor (ER), which is a key driver in the growth of certain types of breast cancer.
Mechanism of Action[edit | edit source]
Imlunestrant functions by binding to the estrogen receptor and inducing a conformational change that leads to the receptor's degradation. This process effectively reduces the number of functional estrogen receptors available in the cell, thereby inhibiting the estrogen-driven proliferation of cancer cells. Unlike selective estrogen receptor modulators (SERMs), which block the receptor, SERDs like Imlunestrant lead to the destruction of the receptor itself.
Clinical Development[edit | edit source]
Imlunestrant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with hormone receptor-positive breast cancer. These trials aim to determine the optimal dosing regimen and to assess the drug's effectiveness in comparison to existing therapies such as tamoxifen and fulvestrant.
Potential Benefits[edit | edit source]
The development of Imlunestrant represents a significant advancement in the treatment of hormone receptor-positive breast cancer. By degrading the estrogen receptor, Imlunestrant may overcome resistance mechanisms that limit the effectiveness of other hormonal therapies. This could potentially lead to improved outcomes for patients who have developed resistance to current treatments.
Side Effects[edit | edit source]
As with any therapeutic agent, Imlunestrant may have side effects. Commonly observed side effects in clinical trials include nausea, fatigue, and hot flashes. Ongoing studies continue to monitor the safety profile of Imlunestrant to ensure its benefits outweigh any potential risks.
Related pages[edit | edit source]
Imlunestrant
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
